Continuous Glucose Monitors

Wearable sensors and software for tracking blood glucose and guiding diabetes treatment.

Core metadata

ID: continuous_glucose_monitors
Era: Modern
First known date: 1999 (exact)
Region: United States and global diabetes care
Review status: source_checked
Maturity: N/A

Prerequisites

Dependents

None.

Fields

None.

Node sources

FDA Executive Summary: Eversense Continuous Glucose Monitoring System (U.S. Food and Drug Administration, 2018, official_agency) • Supports: node, maturity
Glucose Biosensors: An Overview of Use in Clinical Practice (Sensors (Basel) / PubMed Central, 2010, review) • Supports: node, maturity

Prerequisite edge evidence

Edge/source evidence summary:

Prerequisite edges: 3
Average edge confidence: 83%
Prerequisite sources: 3
review: 3

Prerequisite	Type	Confidence	Evidence level	Note	Sources
Glucose Biosensors (glucose_biosensors)	required	90%	review	CGMs require a glucose-sensing element; the first FDA-approved CGM systems used sensor technology to measure glucose continuously rather than occasional finger-stick readings.	FDA Executive Summary: Eversense Continuous Glucose Monitoring System (U.S. Food and Drug Administration, 2018, official_agency) • Supports: edge
Insulin Therapy (insulin_therapy)	enabling	74%	review	CGMs are primarily diabetes-management tools that support glucose tracking and treatment decisions, including insulin dosing workflows.	FDA Executive Summary: Eversense Continuous Glucose Monitoring System (U.S. Food and Drug Administration, 2018, official_agency) • Supports: edge
Electronics (electronics)	required	84%	review	CGMs require electronic sensing, signal processing, and transmission or readout hardware to convert glucose measurements into continuous readings.	FDA Executive Summary: Eversense Continuous Glucose Monitoring System (U.S. Food and Drug Administration, 2018, official_agency) • Supports: edge

This page is generated from canonical era JSON and is indexable by URL.